KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EBT: 2009-2024

Historic EBT for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $557.1 million.

  • Halozyme Therapeutics' EBT rose 32.58% to $219.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $745.9 million, marking a year-over-year increase of 55.37%. This contributed to the annual value of $557.1 million for FY2024, which is 59.94% up from last year.
  • As of FY2024, Halozyme Therapeutics' EBT stood at $557.1 million, which was up 59.94% from $348.3 million recorded in FY2023.
  • Halozyme Therapeutics' EBT's 5-year high stood at $557.1 million during FY2024, with a 5-year trough of $129.3 million in FY2020.
  • In the last 3 years, Halozyme Therapeutics' EBT had a median value of $348.3 million in 2023 and averaged $384.8 million.
  • Data for Halozyme Therapeutics' EBT shows a peak YoY soared of 278.96% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' EBT stood at $129.3 million in 2020, then surged by 92.20% to $248.5 million in 2021, then increased by 0.16% to $248.9 million in 2022, then skyrocketed by 39.94% to $348.3 million in 2023, then spiked by 59.94% to $557.1 million in 2024.